Background {#sec0001}
==========

The Hospital Readmissions Reduction Program (HRRP) has been associated with substantial reductions in readmission within 30 days of discharge among fee-for-service Medicare beneficiaries aged ≥65 years who are hospitalized with acute myocardial infarction, heart failure, or pneumonia---the target population for this program.[@bib0001], [@bib0002] There have been suggestions that hospitals might have pursued reductions in readmissions through efforts mainly directed toward Medicare beneficiaries aged ≥65 years without pursuing systematic improvements in the care of patients.[@bib0003] Other reports have suggested an inconsistent cross-sectional association between hospital-level readmission rates for Medicare beneficiaries for conditions covered under the HRRP compared with other patient groups.[@bib0004], [@bib0005] However, an assessment of the temporal association between the HRRP\'s introduction and changes in readmissions for patient groups other than the Medicare beneficiaries targeted in the program is essential to assess how rates of readmission have evolved in an era with emphasis on readmission reduction for patients who were not directly being targeted for quality improvement nationally.

Accordingly, we used the Healthcare Cost and Utilization Project\'s Nationwide Readmissions Database (NRD), a nationally representative all-payer database, for 2010-2015 to assess temporal trends in 30-day readmission rates for the 3 HRRP target conditions (acute myocardial infarction, heart failure, and pneumonia) and other conditions not targeted by the HRRP, across age-insurance groups.

Methods {#sec0002}
=======

Data Source and Variables {#sec0003}
-------------------------

We used the NRD for the years 2010-2015.[@bib0006] The NRD is a nationally representative, all-payer dataset that has been constructed using discharge-level data for all hospitalizations from the Healthcare Cost and Utilization Project\'s State Inpatient Databases of geographically dispersed participating states (18-27 states during 2010-2015). The sample includes nearly half of all US hospitalizations each year. In 2015, for example, the NRD included 56.6% of hospitalizations in the United States, representing all hospitalizations for 57.8% of the total population. The NRD uses a year-specific, patient-level identifier that allows tracking of patients across hospitalizations in a state within a calendar year.

The NRD includes clinical and demographic variables for each hospitalization and information on the primary insurance payer for each hospitalization. To ensure the uniformity of coding across different data sources, the payer in NRD is classified into broad insurance groups of Medicare, Medicaid, private insurance, self-pay, no charge, other, and missing or invalid. For this study, we included the patients with Medicare, Medicaid, or private insurance as the payers of the hospitalization; Medicare and Medicaid both include fee-for-service and managed care patients, and private insurance includes commercial insurance providers. Given the variability in reporting across participating states, only 1 payer is associated with each person in the NRD. In patients with more than 1 source of insurance coverage, only the insurance program expected to reimburse the hospital for the clinical encounter (the primary payer) is included in the NRD.

Study Population {#sec0004}
----------------

We included all hospitalizations among adults (≥18 years) with a primary discharge diagnosis of acute myocardial infarction, heart failure, and pneumonia, identified using the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes for discharges between January 2010 and September 2015, and the *International Classification of Diseases, Tenth Revision, Clinical Modification* (ICD-10-CM) codes for discharges between October and December 2015. These definitions are consistent with those used by the Centers for Medicare & Medicaid Services (CMS) for its readmission metrics for the respective conditions.[@bib0007], [@bib0008], [@bib0009] We also identified nontarget conditions, representing hospitalizations for conditions that were not subject to financial penalties under the HRRP. To define index hospitalizations for nontarget conditions, we excluded the hospitalizations for the 3 target conditions (acute myocardial infarction, heart failure, and pneumonia). We also excluded hospitalizations for chronic obstructive pulmonary disease and hip and knee arthroplasty because these types were included in the HRRP toward the end of the study period.[@bib0010] The ICD-9-CM and ICD-10-CM codes used to identify each of these conditions are included in [Supplementary Tables 1](#tbl0003){ref-type="table"}-[10](#tbl0012){ref-type="table"} (available online). We stratified all hospitalizations into age-insurance subgroups defined by age (≥65 years or \<65 years) and insurance payer (Medicare, Medicaid, or private insurance).

For each of the 4 conditions (acute myocardial infarction, heart failure, pneumonia, and nontarget hospitalizations), there were 6 age-insurance groups based on age and insurance payer: ≥65 years with Medicare, Medicaid, or private insurance, and \<65 years with Medicare, Medicaid, or private insurance.

Outcome {#sec0005}
-------

The outcome of interest was all-cause 30-day readmission. Readmission was defined as any hospitalization within 30 days of the discharge after an index hospitalization to the same or a different hospital within the state. A hospitalization classified as a readmission was not an index hospitalization for a subsequent readmission event. Data in the NRD are restricted to calendar years, without an ability to track patients across years. Therefore, as recommended by the Agency for Healthcare Research and Quality, we used data for 11 months (January-November) to allow 30-day follow-up for all patients for each year in the analyses.[@bib0011]

Statistical Analysis {#sec0006}
--------------------

We defined an index hospitalization as one in which patients were discharged alive and did not leave the hospital against medical advice. Further, hospitalizations with missing information on either the date of admission or hospital length of stay were excluded because that information was required for the assessment of postdischarge, 30-day events. Multiple index admissions were possible for each patient, regardless of the time elapsed between 2 hospitalizations.

To account for the complex survey design of the NRD, we used survey-specific methodology with hospital as cluster, NRD stratum as strata, and discharge-level weights as weight to obtain weighted nationwide, annual 30-day readmission rates and further evaluate the risk-adjusted annual trends in readmission.[@bib0011], [@bib0012], [@bib0013] For risk adjustment, we created a patient-level survey logistic regression model with 30-day readmission as the outcome and risk factors that are part of the risk adjustment in the CMS publicly reported measure for acute myocardial infarction, heart failure, and pneumonia (age, gender, and comorbidities) based on the secondary diagnoses in the index hospitalization as independent variables. For nontarget conditions, we used the set of risk factors that are included in the CMS hospital-wide readmission measure.[@bib0014] In contrast to the CMS measures, where risk factors are defined based on the diagnoses in the index hospitalization as well as a preceding 12-month period before the index event, the comorbidities used in our survey logistic regression were defined in the index event. To allow assessment of risk-adjusted odds of readmission over years, we assessed calendar year as a dummy coded continuous variable in the model, allowing for an assessment of odds of annual changes in readmission stratified by the 6 age-insurance groups. To further evaluate the differences in annual trends of readmission between older Medicare and other patient groups, we tested the interaction between the calendar year and age-payer patient groups with Medicare patients aged ≥65 years as the reference group.

All analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC), and the level of significance was set at 0.05. The study was exempted by the institutional review board at Yale University (New Haven, Conn) because the data were de-identified. The data are available publicly through the Agency for Healthcare Research and Quality.

Results {#sec0007}
=======

Between 2010 and 2015, there were 1,051,140 hospitalizations for acute myocardial infarction, 2,128,140 for heart failure, 2,067,240 for pneumonia, and 53,734,220 for nontarget conditions in the NRD, representing an estimated 2,364,371, 4,795,327, 4,900,012, and 121,093,299 hospitalizations nationally for acute myocardial infarction, heart failure, pneumonia, and nontarget conditions, respectively ([Supplementary Figure 1](#fig0003){ref-type="fig"}, available online). Overall, there were an estimated 349,139 readmissions nationally for acute myocardial infarction (14.8%), 1,111,593 for heart failure (23.2%), 817,431 for pneumonia (16.7%), and 16,290,748 for nontarget conditions (13.5%). The selected characteristics of index hospitalizations in the 6 patient age-insurance groups for acute myocardial infarction, heart failure, pneumonia, and nontarget conditions are included in [Table 1](#tbl0001){ref-type="table"} , and the characteristics of the patients hospitalized for target conditions are included in [Supplementary Table 11](#tbl0013){ref-type="table"} (available online).Table 1Characteristics of Patients Hospitalized for Acute Myocardial Infarction, Heart Failure, Pneumonia, and Nontarget Conditions Stratified by Age/Insurance GroupsTable 1Patients Aged ≥65 yearsPatients Aged \<65 yearsPatient Characteristics, % (SE)MedicareMedicaidPrivate InsuranceMedicareMedicaidPrivate Insurance**Acute Myocardial Infarction**Age, mean (SE)77.8 (0.03)74.4 (0.1)72.7 (0.07)56.2 (0.03)52.3 (0.04)54.1 (0.02)Female47.4 (0.11)52.9 (0.64)33.1 (0.33)35.9 (0.21)37.3 (0.24)25.4 (0.12)History of coronary artery bypass graft surgery11.3 (0.08)7.5 (0.32)9.2 (0.17)9.8 (0.14)5.2 (0.1)3.2 (0.05)Diabetes mellitus or diabetes mellitus complications38 (0.12)49 (0.61)36.4 (0.3)51.2 (0.24)40.8 (0.24)27.9 (0.13)Iron deficiency or other/unspecified anemias and blood disease28.6 (0.16)33.1 (0.6)23 (0.29)25.3 (0.25)20.8 (0.22)13.2 (0.14)Chronic obstructive pulmonary disease20.3 (0.11)17 (0.5)15.8 (0.23)24.8 (0.24)18.4 (0.23)7.4 (0.09)Renal failure35.4 (0.16)35.6 (0.63)27.2 (0.34)33 (0.32)19.3 (0.24)9.5 (0.11)**Heart Failure**Age, mean (SE)79.9 (0.02)75.6 (0.09)76.1 (0.07)55.3 (0.04)51.7 (0.04)54.3 (0.04)Female54.2 (0.09)61.5 (0.46)43.2 (0.3)41.1 (0.18)42.7 (0.23)37.6 (0.2)History of coronary artery bypass graft surgery18.2 (0.1)13.5 (0.3)17.9 (0.24)12.2 (0.13)7.6 (0.1)9.2 (0.12)Diabetes mellitus or diabetes mellitus complications43.4 (0.1)52.8 (0.43)46.6 (0.29)58.1 (0.21)48.2 (0.21)47.9 (0.21)Iron deficiency or other/unspecified anemias and blood disease35.2 (0.14)38.4 (0.41)31.1 (0.28)34.7 (0.23)29.7 (0.2)26.5 (0.21)Chronic obstructive pulmonary disease34 (0.11)28.7 (0.46)31.9 (0.29)35.8 (0.22)31.3 (0.23)20 (0.18)Renal failure52.6 (0.14)51.9 (0.44)50.7 (0.32)57.1 (0.24)44.3 (0.28)41 (0.26)**Pneumonia**Age, mean (SE)79.8 (0.02)76.5 (0.09)75.6 (0.09)53.5 (0.04)47.1 (0.06)49.9 (0.05)Female53.1 (0.08)58.3 (0.51)44.4 (0.33)49.3 (0.18)55 (0.19)52 (0.16)History of coronary artery bypass graft surgery8.2 (0.06)4.6 (0.19)7.6 (0.15)3.4 (0.06)1.8 (0.05)1.9 (0.04)Diabetes mellitus or diabetes mellitus complications31 (0.09)39.3 (0.47)31.2 (0.27)34.4 (0.18)26.5 (0.17)22.7 (0.13)Iron deficiency or other/unspecified anemias and blood disease33.5 (0.16)36.1 (0.48)29.7 (0.3)31.7 (0.22)28.9 (0.2)24.9 (0.18)Chronic obstructive pulmonary disease41.2 (0.13)35.2 (0.53)40.8 (0.32)39.6 (0.25)33.8 (0.25)21.5 (0.17)Renal failure30.1 (0.12)28.4 (0.46)26.4 (0.31)25.3 (0.19)14.7 (0.16)12.1 (0.12)**Nontarget Conditions**Age, mean77.7 (0.02)74.4 (0.05)73.1 (0.05)51.1 (0.03)36.4 (0.06)42 (0.06)Female57.3 (0.05)60.9 (0.34)47 (0.15)50.8 (0.07)72.8 (0.18)67.8 (0.19)Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance32.7 (0.1)32.8 (0.24)27.4 (0.12)30.7 (0.13)15.3 (0.1)14 (0.08)Diabetes mellitus31.7 (0.07)40.2 (0.22)30.4 (0.1)34.6 (0.1)14.1 (0.07)12.6 (0.07)Iron deficiency or other/unspecified anemias and blood disease31.3 (0.12)32.1 (0.25)26.5 (0.14)27.3 (0.18)18.7 (0.13)15.7 (0.11)Chronic obstructive pulmonary disease18.1 (0.06)14.5 (0.21)14.6 (0.1)16.4 (0.1)6 (0.06)3.2 (0.03)Renal failure28 (0.1)27.7 (0.23)22.2 (0.14)25.4 (0.15)7.4 (0.07)5.9 (0.06)[^1]

Readmission Trends for Target Conditions {#sec0008}
----------------------------------------

Over the 6 years of the study period (2010-2015), 30-day readmission rates for acute myocardial infarction decreased for all 6 age-insurance groups ([Figures 1](#fig0001){ref-type="fig"} A and [2](#fig0002){ref-type="fig"} A) ([Supplementary Table 12](#tbl0014){ref-type="table"}, available online). The baseline characteristics of the patients hospitalized for acute myocardial infarction are shown in [Supplementary Table 13](#tbl0015){ref-type="table"} (available online). In those who were aged ≥65 years and covered by Medicare, readmission rates decreased from 19.2% in 2010 to 15.8% in 2015 (risk-adjusted odds ratio \[OR\] for yearly change in readmission, 0.94; 95% confidence interval \[CI\], 0.94-0.95) ([Table 2](#tbl0002){ref-type="table"} and [Supplementary Figure 2](#fig0004){ref-type="fig"} \[available online\]). In those aged ≥65 years, readmission rates decreased from 14.6% to 12.4% (risk-adjusted OR, 0.95; 95% CI, 0.93-0.97) for the privately insured, and from 23.4% to 18.3% (risk-adjusted OR, 0.93; 95% CI, 0.90-0.97) for those insured by Medicaid. Privately insured and Medicaid patients aged \<65 years had a relative decline in readmission rates (privately insured: risk-adjusted OR, 0.93, 95% CI, 0.92-0.94; Medicaid: risk-adjusted OR, 0.94, 95% CI, 0.92-0.95) similar to that of the Medicare population aged ≥65 years. Medicare patients aged \<65 years also observed a decrease in readmission rates (19.7% to 18.6%; risk-adjusted OR, 0.97, 95% CI, 0.96-0.98), but the decrease was lower than that of the reference group of Medicare aged ≥65 years (*P* for calendar-year\*age-insurance group interaction, .001).Figure 1Trends of readmission rates in patients aged ≥65 years by different payer types.Fig 1Figure 2Trends of readmission rates in patients aged \<65 years by different payer types.Fig 2Supplementary Figure 1.Patient Selection Flowsheet. AMI= acute myocardial infarction; COPD= chronic obstructive pulmonary disease; HF= heart failure; H/K= hip/knee replacement; NRD= National Readmission Database; PN= pneumoniaFig 3Table 2Risk Adjusted Odds Ratios for Annual Decrease in Readmission Rates by Age-Payer GroupsTable 2Odds Ratio (95% CI)**Acute Myocardial Infarction**Medicare patients aged ≥65 years0.94 (0.94-0.95)Medicaid patients aged ≥65 years0.93 (0.90-0.97)Private insurance patients aged ≥65 years0.95 (0.93-0.97)Medicare patients aged \<65 years0.97 (0.96-0.98)Medicaid patients aged \<65 years0.94 (0.92-0.95)Private insurance patients aged \<65 years0.93 (0.92-0.94)**Heart Failure**Medicare patients aged ≥65 years0.96 (0.96-0.97)Medicaid patients aged ≥65 years0.96 (0.94-0.98)Private insurance patients aged ≥65 years0.97 (0.96-0.99)Medicare patients aged \<65 years0.98 (0.97-0.98)Medicaid patients aged \<65 years0.96 (0.96-0.97)Private insurance patients aged \<65 years0.97 (0.95-0.98)**Pneumonia**Medicare patients aged ≥65 years0.96 (0.96-0.97)Medicaid patients aged ≥65 years0.94 (0.92-0.96)Private insurance patients aged ≥65 years0.96 (0.95-0.97)Medicare patients aged \<65 years0.98 (0.97-0.99)Medicaid patients aged \<65 years0.98 (0.97-0.99)Private insurance patients aged \<65 years0.98 (0.97-1.00)**Nontarget Conditions**Medicare patients aged ≥65 years0.97 (0.97-0.97)Medicaid patients aged ≥65 years0.98 (0.96-0.99)Private insurance patients aged ≥65 years0.97 (0.97-0.98)Medicare patients aged \<65 years0.98 (0.98-0.99)Medicaid patients aged \<65 years0.97 (0.96-0.98)Private insurance patients aged \<65 years0.98 (0.97-0.98)Supplementary Table 1:ICD-9 Codes Used to Define AMI CohorteTable 1ICD-9-CM Diagnosis CodesDescription410.00Acute myocardial infarction of anterolateral wall, episode of care unspecified410.01Acute myocardial infarction of anterolateral wall, initial episode of care410.10Acute myocardial infarction of other anterior wall, episode of care unspecified410.11Acute myocardial infarction of other anterior wall, initial episode of care410.20Acute myocardial infarction of inferolateral wall, episode of care unspecified410.21Acute myocardial infarction of inferolateral wall, initial episode of care410.30Acute myocardial infarction of inferoposterior wall, episode of care unspecified410.31Acute myocardial infarction of inferoposterior wall, initial episode of care410.40Acute myocardial infarction of other inferior wall, episode of care unspecified410.41Acute myocardial infarction of other inferior wall, initial episode of care410.50Acute myocardial infarction of other lateral wall, episode of care unspecified410.51Acute myocardial infarction of other lateral wall, initial episode of care410.60True posterior wall infarction, episode of care unspecified410.61True posterior wall infarction, initial episode of care410.70Subendocardial infarction, episode of care unspecified410.71Subendocardial infarction, initial episode of care410.80Acute myocardial infarction of other specified sites, episode of care unspecified410.81Acute myocardial infarction of other specified sites, initial episode of care410.90Acute myocardial infarction of unspecified site, episode of care unspecified410.91Acute myocardial infarction of unspecified site, initial episode of careSupplementary Table 2:ICD-9 Codes Used to Define Heart Failure CohorteTable 2ICD-9-CM Diagnosis CodesDescription402.01Malignant hypertensive heart disease with heart failure402.11Benign hypertensive heart disease with heart failure402.91Unspecified hypertensive heart disease with heart failure404.01Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.03Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease404.11Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.13Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease404.91Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.93Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease428.0Congestive heart failure, unspecified428.1Left heart failure428.20Systolic heart failure, unspecified428.21Acute systolic heart failure428.22Chronic systolic heart failure428.23Acute on chronic systolic heart failure428.30Diastolic heart failure, unspecified428.31Acute diastolic heart failure428.32Chronic diastolic heart failure428.33Acute on chronic diastolic heart failure428.40Combined systolic and diastolic heart failure, unspecified428.41Acute combined systolic and diastolic heart failure428.42Chronic combined systolic and diastolic heart failure428.43Acute on chronic combined systolic and diastolic heart failure428.9Heart failure, unspecifiedSupplementary Table 3:ICD-9 Codes Used to Define Pneumonia CohorteTable 3ICD-9-CM Diagnosis CodesDescription480.0Pneumonia due to adenovirus480.1Pneumonia due to respiratory syncytial virus480.2Pneumonia due to parainfluenza virus480.3Pneumonia due to SARS-associated coronavirus480.8Pneumonia due to other virus not elsewhere classified480.9Viral pneumonia, unspecified481Pneumococcal pneumonia \[Streptococcus pneumoniae pneumonia\]482.0Pneumonia due to Klebsiella pneumoniae482.1Pneumonia due to Pseudomonas482.2Pneumonia due to Hemophilus influenzae \[H. influenzae\]482.30Pneumonia due to Streptococcus, unspecified482.31Pneumonia due to Streptococcus, group A482.32Pneumonia due to Streptococcus, group B482.39Pneumonia due to other Streptococcus482.40Pneumonia due to Staphylococcus, unspecified482.41Methicillin susceptible pneumonia due to Staphylococcus aureus482.42Methicillin resistant pneumonia due to Staphylococcus aureus482.49Other Staphylococcus pneumonia482.81Pneumonia due to anaerobes482.82Pneumonia due to escherichia coli \[E. coli\]482.83Pneumonia due to other gram-negative bacteria482.84Pneumonia due to Legionnaires\' disease482.89Pneumonia due to other specified bacteria482.9Bacterial pneumonia, unspecified483.0Pneumonia due to mycoplasma pneumoniae483.1Pneumonia due to chlamydia483.8Pneumonia due to other specified organism485Bronchopneumonia, organism unspecified486Pneumonia, organism unspecified487.0Influenza with pneumonia488.11Influenza due to identified 2009 H1N1 influenza virus with pneumonia507.0Pneumonitis due to inhalation of food or vomitusSupplementary Table 4:ICD-9 Codes Used to Define Chronic Obstructive Pulmonary Disease CohorteTable 4ICD-9-CM Diagnosis CodesDescription491.21Obstructive chronic bronchitis with (acute) exacerbation491.22Obstructive chronic bronchitis with acute bronchitis491.8Other chronic bronchitis491.9Unspecified chronic bronchitis492.8Other emphysema493.20Chronic obstructive asthma, unspecified493.21Chronic obstructive asthma with status asthmaticus493.22Chronic obstructive asthma with (acute) exacerbation496Chronic airway obstruction, not elsewhere classifiedPrincipal discharge diagnosis codes included in cohort if combined with a secondary diagnosis of COPD with exacerbation (491.21, 491.22, 493.21, or 493.22)518.81Acute respiratory failure518.82Other pulmonary insufficiency, not elsewhere classified518.84Acute and chronic respiratory failure799.1Respiratory arrestSupplementary Table 5:ICD-9 Codes Used to Define Hip/Knee Arthroplasty CohorteTable 5ICD-9-CM Procedure CodesDescription81.51Total hip replacement81.54Total knee replacementSupplementary Table 6:ICD-10 Codes Used to Define Acute Myocardial InfarctioneTable 6ICD-10-CM CodesDescriptionI21.01ST elevation (STEMI) myocardial infarction involving left main coronary arteryI21.02ST elevation (STEMI) myocardial infarction involving left anterior descending coronary arteryI21.09ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wallI21.11ST elevation (STEMI) myocardial infarction involving right coronary arteryI21.19ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wallI21.21ST elevation (STEMI) myocardial infarction involving left circumflex coronary arteryI21.29ST elevation (STEMI) myocardial infarction involving other sitesI21.3ST elevation (STEMI) myocardial infarction of unspecified siteI21.4Non-ST elevation (NSTEMI) myocardial infarctionSupplementary Table 7:ICD-10 Codes Used to Define Heart FailureeTable 7ICD-10-CM CodesDescriptionI11.0Hypertensive heart disease with heart failureI13.0Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney diseaseI13.2Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal diseaseI50.1Left ventricular failureI50.20Unspecified systolic (congestive) heart failureI50.21Acute systolic (congestive) heart failureI50.22Chronic systolic (congestive) heart failureI50.23Acute on chronic systolic (congestive) heart failureI50.30Unspecified diastolic (congestive) heart failureI50.31Acute diastolic (congestive) heart failureI50.32Chronic diastolic (congestive) heart failureI50.33Acute on chronic diastolic (congestive) heart failureI50.40Unspecified combined systolic (congestive) and diastolic (congestive) heart failureI50.41Acute combined systolic (congestive) and diastolic (congestive) heart failureI50.42Chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.43Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.9Heart failure, unspecifiedSupplementary Table 8:ICD-10 Codes Used to Define PneumoniaeTable 8ICD-10-CM CodesDescriptionA48.1Legionnaires\' diseaseJ10.00Influenza due to other identified influenza virus with unspecified type of pneumoniaJ10.01Influenza due to other identified influenza virus with the same other identified influenza virus pneumoniaJ10.08Influenza due to other identified influenza virus with other specified pneumoniaJ11.00Influenza due to unidentified influenza virus with unspecified type of pneumoniaJ11.08Influenza due to unidentified influenza virus with specified pneumoniaJ12.0Adenoviral pneumoniaJ12.1Respiratory syncytial virus pneumoniaJ12.2Parainfluenza virus pneumoniaJ12.3Human metapneumovirus pneumoniaJ12.81Pneumonia due to SARS-associated coronavirusJ12.89Other viral pneumoniaJ12.9Viral pneumonia, unspecifiedJ13Pneumonia due to Streptococcus pneumoniaeJ14Pneumonia due to Hemophilus influenzaeJ15.0Pneumonia due to Klebsiella pneumoniaeJ15.1Pneumonia due to PseudomonasJ15.20Pneumonia due to staphylococcus, unspecifiedJ15.211Pneumonia due to Methicillin susceptible Staphylococcus aureusJ15.212Pneumonia due to Methicillin resistant Staphylococcus aureusJ15.29Pneumonia due to other staphylococcusJ15.3Pneumonia due to streptococcus, group BJ15.4Pneumonia due to other streptococciJ15.5Pneumonia due to Escherichia coliJ15.6Pneumonia due to other aerobic Gram-negative bacteriaJ15.7Pneumonia due to Mycoplasma pneumoniaeJ15.8Pneumonia due to other specified bacteriaJ15.9Unspecified bacterial pneumoniaJ16.0Chlamydial pneumoniaJ16.8Pneumonia due to other specified infectious organismsJ18.0Bronchopneumonia, unspecified organismJ18.1Lobar pneumonia, unspecified organismJ18.8Other pneumonia, unspecified organismJ18.9Pneumonia, unspecified organismJ69.0Pneumonitis due to inhalation of food and vomitSupplementary Table 9:ICD-10 Codes Used to Define Chronic Obstructive Pulmonary DiseaseeTable 9ICD-10-CM CodesDescriptionJ41.8Mixed simple and mucopurulent chronic bronchitisJ42Unspecified chronic bronchitisJ43.0Unilateral pulmonary emphysema \[MacLeod\'s syndrome\]J43.1Panlobular emphysemaJ43.2Centrilobular emphysemaJ43.8Other emphysemaJ43.9Emphysema, unspecifiedJ44.0Chronic obstructive pulmonary disease with acute lower respiratory infectionJ44.1Chronic obstructive pulmonary disease with (acute) exacerbationJ44.9Chronic obstructive pulmonary disease, unspecifiedPrincipal discharge diagnosis codes included in cohort if combined with a secondary diagnosis of J44.0 or J44.1J96.00Acute respiratory failure, unspecified whether with hypoxia or hypercapniaJ96.01Acute respiratory failure with hypoxiaJ96.02Acute respiratory failure with hypercapniaJ96.20Acute and chronic respiratory failure, unspecified whether with hypoxia or hypercapniaJ96.21Acute and chronic respiratory failure with hypoxiaJ96.22Acute and chronic respiratory failure with hypercapniaJ96.90Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapniaJ96.91Respiratory failure, unspecified with hypoxiaJ96.92Respiratory failure, unspecified with hypercapniaR09.2Respiratory arrestSupplementary Table 10:ICD-10 Codes Used to Define Hip/Knee ArthroplastyeTable 10ICD-10-PCS CodesDescription0SR9019Replacement of Right Hip Joint with Metal Synthetic Substitute, Cemented, Open Approach0SR901AReplacement of Right Hip Joint with Metal Synthetic Substitute, Uncemented, Open Approach0SR901ZReplacement of Right Hip Joint with Metal Synthetic Substitute, Open Approach0SR9029Replacement of Right Hip Joint with Metal on Polyethylene Synthetic Substitute, Cemented, Open Approach0SR902AReplacement of Right Hip Joint with Metal on Polyethylene Synthetic Substitute, Uncemented, Open Approach0SR902ZReplacement of Right Hip Joint with Metal on Polyethylene Synthetic Substitute, Open Approach0SR9039Replacement of Right Hip Joint with Ceramic Synthetic Substitute, Cemented, Open Approach0SR903AReplacement of Right Hip Joint with Ceramic Synthetic Substitute, Uncemented, Open Approach0SR903ZReplacement of Right Hip Joint with Ceramic Synthetic Substitute, Open Approach0SR9049Replacement of Right Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Cemented, Open Approach0SR904AReplacement of Right Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Uncemented, Open Approach0SR904ZReplacement of Right Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Open Approach0SR90J9Replacement of Right Hip Joint with Synthetic Substitute, Cemented, Open Approach0SR90JAReplacement of Right Hip Joint with Synthetic Substitute, Uncemented, Open Approach0SR90JZReplacement of Right Hip Joint with Synthetic Substitute, Open Approach0SRB019Replacement of Left Hip Joint with Metal Synthetic Substitute, Cemented, Open Approach0SRB01AReplacement of Left Hip Joint with Metal Synthetic Substitute, Uncemented, Open Approach0SRB01ZReplacement of Left Hip Joint with Metal Synthetic Substitute, Open Approach0SRB029Replacement of Left Hip Joint with Metal on Polyethylene Synthetic Substitute, Cemented, Open Approach0SRB02AReplacement of Left Hip Joint with Metal on Polyethylene Synthetic Substitute, Uncemented, Open Approach0SRB02ZReplacement of Left Hip Joint with Metal on Polyethylene Synthetic Substitute, Open Approach0SRB039Replacement of Left Hip Joint with Ceramic Synthetic Substitute, Cemented, Open Approach0SRB03AReplacement of Left Hip Joint with Ceramic Synthetic Substitute, Uncemented, Open Approach0SRB03ZReplacement of Left Hip Joint with Ceramic Synthetic Substitute, Open Approach0SRB049Replacement of Left Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Cemented, Open Approach0SRB04AReplacement of Left Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Uncemented, Open Approach0SRB04ZReplacement of Left Hip Joint with Ceramic on Polyethylene Synthetic Substitute, Open Approach0SRB0J9Replacement of Left Hip Joint with Synthetic Substitute, Cemented, Open Approach0SRB0JAReplacement of Left Hip Joint with Synthetic Substitute, Uncemented, Open Approach0SRB0JZReplacement of Left Hip Joint with Synthetic Substitute, Open Approach0SRC0J9Replacement of Right Knee Joint with Synthetic Substitute, Cemented, Open Approach0SRC0JAReplacement of Right Knee Joint with Synthetic Substitute, Uncemented, Open Approach0SRC0JZReplacement of Right Knee Joint with Synthetic Substitute, Open Approach0SRD0J9Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach0SRD0JAReplacement of Left Knee Joint with Synthetic Substitute, Uncemented, Open Approach0SRD0JZReplacement of Left Knee Joint with Synthetic Substitute, Open ApproachSupplementary Figure 2.Risk-Adjusted Odds Ratios for Yearly Change in Readmission Rates, According to Different Age-Payer Groups. CI= confidence interval; OR= odds ratioFig 4

Similar to acute myocardial infarction, all-cause 30-day readmission rates for heart failure decreased in all age-insurance groups between 2010 and 2015, with a similar relative decline in all groups (*P* for calendar-year\*age-insurance group interaction, .056) ([Figures 1](#fig0001){ref-type="fig"}B and [2](#fig0002){ref-type="fig"}B) ([Supplementary Table 11](#tbl0013){ref-type="table"} , available online). The baseline characteristics of the patients hospitalized for heart failure are shown in [Supplementary Table 14](#tbl0016){ref-type="table"} (available online). In patients aged ≥65 years, readmission rates decreased from 23.6% in 2010 to 21.8% in 2015 in those covered by Medicare (risk-adjusted OR for yearly change in readmission, 0.96; 95% CI, 0.96-0.98), from 26.4% to 24.1% in those covered by Medicaid (risk-adjusted OR, 0.96; 95% CI, 0.94-0.98), and from 20.5% to 20.2% in those privately insured (risk-adjusted OR, 0.97; 95% CI, 0.96-0.99) ([Table 2](#tbl0002){ref-type="table"} and [Supplementary Figure 2](#fig0004){ref-type="fig"} \[available online\]). For those aged \<65 years and covered by Medicare, readmission rates increased from 28.9% in 2010 to 29.2% in 2011 and decreased to 28.0% in 2015 (risk-adjusted OR, 0.98; 95% CI, 0.97-0.98). In this age group, readmissions decreased uniformly across the study period for both Medicaid (risk-adjusted OR, 0.97; 95% CI, 0.96-0.98) and privately insured (risk-adjusted OR, 0.97; 95% CI, 0.95-0.98) patients.Supplementary Table 11:Characteristics of Patients Hospitalized for Acute Myocardial Infarction, Heart Failure and Pneumonia According to the Primary PayereTable 11:**Patients aged ≥65 yearsPatients aged \<65 yearsPatient Characteristics, % (SE)MedicareMedicaidPrivate InsuranceMedicareMedicaidPrivate Insurance**No. of Index Admissions, weighted (SD)7824671 (63563)109437 (2181)434416 (7463)1215957 (12753)953466 (12010)1521762 (14695)Acute Myocardial Infarction1310180 (13862)17337 (417)98738 (1767)186158 (2625)165828 (2406)586130 (7136)Congestive Heart Failure3354561 (27782)49455 (1149)169450 (3221)487817 (6787)386078 (6437)347967 (4435)Pneumonia3159930 (26032)42646 (829)166229 (3083)541983 (5010)401560 (4333)587665 (5549)Age, mean (SE)79.5 (0.02)75.8 (0.07)75.1 (0.07)54.7 (0.03)49.9 (0.03)52.5 (0.02)Female52.6 (0.06)58.9 (0.34)41.4 (0.23)44 (0.11)46.9 (0.15)38.5 (0.12)History of coronary artery bypass graft (CABG) surgery13 (0.07)9 (0.18)12 (0.13)7.9 (0.07)4.7 (0.05)4.1 (0.04)Metastatic cancer or acute leukemia1.7 (0.01)1.4 (0.07)2.2 (0.05)1.4 (0.03)1.9 (0.04)2.3 (0.05)Diabetes mellitus (DM) or DM complications37.5 (0.09)46.9 (0.31)38.4 (0.19)46.6 (0.14)37.8 (0.13)30.5 (0.1)Protein-calorie malnutrition6.2 (0.06)6.2 (0.18)5.1 (0.11)5.1 (0.07)4.6 (0.07)2.7 (0.04)Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance34.3 (0.11)34.8 (0.3)30.5 (0.18)35.8 (0.16)31.2 (0.15)25.3 (0.12)Iron deficiency or other/unspecified anemias and blood disease33.3 (0.13)36.6 (0.31)28.6 (0.19)31.9 (0.18)27.8 (0.15)20.8 (0.13)Dementia or other specified brain disorders17.3 (0.07)14.8 (0.24)9.8 (0.13)2.7 (0.03)1.6 (0.03)0.5 (0.01)Hemiplegia, paraplegia, paralysis, functional disability3.8 (0.02)5.9 (0.13)3 (0.05)9.1 (0.07)6.1 (0.06)2.1 (0.03)Congestive heart failure55.7 (0.13)54.8 (0.36)49.1 (0.25)49.1 (0.24)46.1 (0.25)29.6 (0.19)Acute coronary syndrome3.8 (0.04)4 (0.11)3.6 (0.07)2.7 (0.04)2.7 (0.05)2.3 (0.03)Valvular and rheumatic heart disease18.4 (0.11)14.6 (0.25)14.8 (0.17)9 (0.09)9 (0.1)7.6 (0.08)Specified arrhythmias and other heart rhythm disorders45.2 (0.11)35.3 (0.29)40.2 (0.23)23.5 (0.15)20.4 (0.14)21.5 (0.14)Stroke0.6 (0.01)0.6 (0.04)0.5 (0.02)0.4 (0.01)0.5 (0.01)0.4 (0.01)Vascular or circulatory disease21.1 (0.1)16.4 (0.23)19.2 (0.18)18.6 (0.11)13.7 (0.09)12.2 (0.08)Chronic obstructive pulmonary disease (COPD)34.6 (0.1)29.6 (0.34)31.7 (0.21)35.9 (0.18)30.2 (0.17)15.8 (0.1)Asthma3.2 (0.02)5.5 (0.13)3.8 (0.06)6.4 (0.06)9.2 (0.09)7.8 (0.06)Pneumonia10.2 (0.05)9.9 (0.16)8.7 (0.1)8.2 (0.06)7.5 (0.06)5.7 (0.04)Dialysis status2.3 (0.02)4.6 (0.12)1.6 (0.04)9.1 (0.11)2.6 (0.04)1.2 (0.02)Renal failure40.7 (0.12)40.3 (0.33)36.1 (0.25)39.3 (0.23)27.6 (0.22)17.7 (0.14)Other urinary tract disorders5.4 (0.04)4.9 (0.12)5 (0.08)3.7 (0.04)3.4 (0.04)3.1 (0.04)Decubitus ulcer or chronic skin ulcer5 (0.03)4.8 (0.12)3.7 (0.06)5 (0.05)3.5 (0.04)1.6 (0.02)

Readmission rates for pneumonia decreased across age-insurance groups, but with differences in relative decline across the groups (*P* for calendar year\*age-insurance group interaction \<.001) ([Figures 1](#fig0001){ref-type="fig"}C and [2](#fig0002){ref-type="fig"}C) ([Supplementary Table 11](#tbl0013){ref-type="table"}, available online). The baseline characteristics of the patients hospitalized for pneumonia are shown in [Supplementary Table 15](#tbl0017){ref-type="table"} (available online). Among those aged ≥65 years, readmission rates decreased from 18.1% in 2010 to 16.1% in 2015 in those covered by Medicare (risk-adjusted OR for yearly change in readmission, 0.96; 95% CI, 0.96-0.97), from 20.6% to 17.1% in those covered by Medicaid (risk-adjusted OR, 0.94; 95% CI, 0.92-0.96), and from 16.5% to 14.7% in the privately insured (risk-adjusted OR, 0.96; 95% CI, 0.96-0.97) ([Table 2](#tbl0002){ref-type="table"} and [Supplementary Figure 2](#fig0004){ref-type="fig"} \[available online\]). There was a much smaller relative decrease in readmission rates for all insurance groups in the aged \<65 years age group, relative to the trends in the reference group of those covered by Medicare and who were aged ≥65 years (*P* for calendar year\*age-insurance interaction \<.05 for all groups aged \<65 years). Specifically, in this age group, readmission rates decreased from 20.1% in 2010 to 19.4% in 2015 for those covered by Medicare (risk-adjusted OR, 0.98; 95% CI, 0.97-0.99), from 18.2% to 17.4% for Medicaid patients (risk-adjusted OR, 0.98; 95% CI, 0.97-0.99), and from 11.0% to 10.9% for the privately insured (risk-adjusted OR, 0.98; 95% CI, 0.97-1.00).

Readmission Trends for Nontarget Conditions {#sec0009}
-------------------------------------------

Patients hospitalized for nontarget conditions who were covered by either Medicare or Medicaid were more frequently readmitted than patients who were privately insured; this was found in patients both aged \>65 and \<65 years. Further, there was a small decrease in observed readmission rates in most age-insurance groups ([Figures 1](#fig0001){ref-type="fig"}D and [2](#fig0002){ref-type="fig"}D) ([Supplementary Table 12](#tbl0014){ref-type="table"} , available online). In patients aged ≥65 years who were covered by Medicare, readmission rates decreased from 16.3% in 2010 to 15.5% in 2015 (risk-adjusted OR for yearly change in readmission rates, 0.97; 95% CI, 0.97-0.97) ([Table 2](#tbl0002){ref-type="table"} and [Supplementary Figure 2](#fig0004){ref-type="fig"} \[available online\]). Those covered by Medicaid followed a similar pattern (risk-adjusted OR, 0.98; 95% CI, 0.96-0.99). Among the privately insured, readmission rates decreased from 14.0% in 2010 to 13.5% in 2013, then increased to 13.8% in 2015 (risk-adjusted OR, 0.97; 95% CI, 0.97-0.98). In contrast, there was a small relative decrease in readmission rates in patients aged \<65 years over the study period: 20.8% to 20.5% for those covered by Medicare (risk-adjusted OR, 0.98; 95% CI, 0.98-0.99), 13.1% to 12.9% for those covered by Medicaid (risk-adjusted OR, 0.97; 95% CI, 0.96-0.98), and 8.6% to 8.4% for those privately insured (risk-adjusted OR, 0.98; 95% CI, 0.97-0.98).Supplementary Table 12:Annual Readmission Rates of Acute Myocardial Infarction, Heart Failure, Pneumonia, and Non-Target Conditions.eTable 12:**Readmission Rates (%)201020112012201320142015Acute Myocardial Infarction**Medicare patients aged ≥65 years19.219.017.316.716.115.8Medicaid patients aged ≥65 years23.421.716.718.318.218.3Private Insurance patients aged ≥65 years14.614.113.812.612.512.4Medicare patients aged \<65 years19.719.018.518.018.118.6Medicaid patients aged \<65 years17.617.016.516.413.814.1Private Insurance patients aged \<65 years9.08.47.87.66.87.0**Heart Failure**Medicare patients aged ≥65 years23.623.622.821.921.621.8Medicaid patients aged ≥65 years26.625.826.424.424.224.1Private Insurance patients aged ≥65 years20.521.520.620.020.120.2Medicare patients aged \<65 years28.929.228.728.227.428.0Medicaid patients aged \<65 years29.328.928.227.726.927.2Private Insurance patients aged \<65 years18.917.918.017.117.517.1**Pneumonia**Medicare patients aged ≥65 years18.117.717.516.616.516.1Medicaid patients aged ≥65 years20.619.719.916.516.517.1Private Insurance patients aged ≥65 years16.515.815.514.315.114.7Medicare patients aged \<65 years20.120.119.819.719.519.4Medicaid patients aged \<65 years18.218.418.818.217.317.4Private Insurance patients aged \<65 years11.010.410.810.810.410.9**Non-Target Conditions**Medicare patients aged ≥65 years16.316.315.815.515.515.5Medicaid patients aged ≥65 years18.017.617.917.017.217.6Private Insurance patients aged ≥65 years14.014.213.813.513.513.8Medicare patients aged \<65 years20.820.620.320.320.520.5Medicaid patients aged \<65 years13.113.213.312.912.712.9Private Insurance patients aged \<65 years8.68.68.58.38.38.4Supplementary Table 13:Characteristics of Patients Hospitalized for Acute Myocardial Infarction According to the Primary PayereTable 13:**Patients aged ≥65 yearsPatients aged \<65 yearsPatient Characteristics, N (%)MedicareMedicaidPrivate InsuranceMedicareMedicaidPrivate Insurance**No. of Index Admissions, weighted (SD)1310180 (13862)17337 (417)98738 (1767)186158 (2625)165828 (2406)586130 (7136)Age, mean (SE)77.8 (0.03)74.4 (0.1)72.7 (0.07)56.2 (0.03)52.3 (0.04)54.1 (0.02)Female47.4 (0.11)52.9 (0.64)33.1 (0.33)35.9 (0.21)37.3 (0.24)25.4 (0.12)Anterior myocardial infarction7.6 (0.06)9 (0.33)10 (0.18)8.5 (0.12)13 (0.17)15 (0.11)Other location of myocardial infarction12.1 (0.1)10.5 (0.37)16.5 (0.23)15.3 (0.19)18.2 (0.22)24.4 (0.15)History of coronary artery bypass graft (CABG) surgery11.3 (0.08)7.5 (0.32)9.2 (0.17)9.8 (0.14)5.2 (0.1)3.2 (0.05)History of percutaneous transluminal coronary angioplasty (PTCA)15.7 (0.12)12.1 (0.45)16 (0.26)21 (0.23)15.8 (0.2)12.4 (0.12)Severe infection; other infectious diseases5.6 (0.05)6.7 (0.3)3.8 (0.12)5.3 (0.1)4.4 (0.1)1.9 (0.04)Metastatic cancer or acute leukemia1.1 (0.02)0.9 (0.13)0.9 (0.06)0.6 (0.04)0.6 (0.03)0.4 (0.02)Cancer4.7 (0.04)3.6 (0.32)4.1 (0.13)2.6 (0.08)2.2 (0.07)1.6 (0.03)Diabetes mellitus (DM) or DM complications38 (0.12)49 (0.61)36.4 (0.3)51.2 (0.24)40.8 (0.24)27.9 (0.13)Protein-calorie malnutrition3.4 (0.05)3.9 (0.26)2.2 (0.09)2.3 (0.07)1.9 (0.07)0.7 (0.02)Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance24.9 (0.14)28.1 (0.55)19.8 (0.26)25.3 (0.25)20.4 (0.22)13.3 (0.13)Iron deficiency or other/unspecified anemias and blood disease28.6 (0.16)33.1 (0.6)23 (0.29)25.3 (0.25)20.8 (0.22)13.2 (0.14)Dementia or other specified brain disorders12.1 (0.08)9.9 (0.36)5.4 (0.15)1.5 (0.05)0.8 (0.04)0.2 (0.01)Hemiplegia, paraplegia, paralysis, functional disability3.1 (0.03)4.7 (0.24)2.1 (0.08)6.9 (0.13)3.7 (0.08)0.9 (0.02)Congestive heart failure43 (0.16)46.1 (0.67)32.4 (0.32)36.5 (0.27)29.7 (0.25)15.2 (0.14)Acute coronary syndrome2.4 (0.04)2.7 (0.21)2.6 (0.1)2.6 (0.07)2.9 (0.08)2.5 (0.06)Angina pectoris1.1 (0.03)1.1 (0.14)1 (0.06)1.2 (0.05)1.2 (0.06)1.2 (0.04)Coronary atherosclerosis/other chronic ischemic heart disease81 (0.16)79.3 (0.53)84.5 (0.26)85.2 (0.2)82.4 (0.21)85.8 (0.15)Valvular and rheumatic heart disease17.8 (0.13)14.7 (0.55)13 (0.21)8.5 (0.14)7.3 (0.13)5.6 (0.08)Specified arrhythmias and other heart rhythm disorders41.5 (0.14)34.2 (0.61)36.7 (0.28)24.5 (0.21)22.2 (0.21)22.5 (0.15)Stroke1.2 (0.02)1.6 (0.16)1 (0.05)0.9 (0.04)1.2 (0.05)0.5 (0.02)Cerebrovascular disease6.4 (0.06)5.6 (0.27)4.7 (0.12)4.9 (0.1)3.4 (0.1)1.6 (0.04)Vascular or circulatory disease24.3 (0.13)20.5 (0.52)20.7 (0.26)23.6 (0.2)16.7 (0.18)12.2 (0.11)Chronic obstructive pulmonary disease (COPD)20.3 (0.11)17 (0.5)15.8 (0.23)24.8 (0.24)18.4 (0.23)7.4 (0.09)Asthma2.6 (0.03)4 (0.22)2.9 (0.1)3.8 (0.09)4.8 (0.1)3.3 (0.05)Pneumonia10.1 (0.08)11.9 (0.39)7.6 (0.16)7.6 (0.12)6.7 (0.11)3.5 (0.05)Dialysis status2 (0.03)3.4 (0.21)1.1 (0.06)8 (0.16)1.6 (0.06)0.5 (0.02)Renal failure35.4 (0.16)35.6 (0.63)27.2 (0.34)33 (0.32)19.3 (0.24)9.5 (0.11)Other urinary tract disorders5.3 (0.05)5.1 (0.26)4.7 (0.12)3.2 (0.08)2.7 (0.07)2.2 (0.04)Decubitus ulcer or chronic skin ulcer2.5 (0.03)2.9 (0.22)1.5 (0.07)2.9 (0.07)1.6 (0.05)0.5 (0.02)Supplementary Table 14:Characteristics of Patients Hospitalized for Heart Failure According to the Primary PayereTable 14:**Patients aged ≥65 yearsPatients aged \<65 yearsPatient Characteristics, N (%)MedicareMedicaidPrivate InsuranceMedicareMedicaidPrivate Insurance**No. of Index Admissions, weighted (SD)3354561 (27782)49455 (1149)169450 (3221)487817 (6787)386078 (6437)347967 (4435)Age, mean (SE)79.9 (0.02)75.6 (0.09)76.1 (0.07)55.3 (0.04)51.7 (0.04)54.3 (0.04)Female54.2 (0.09)61.5 (0.46)43.2 (0.3)41.1 (0.18)42.7 (0.23)37.6 (0.2)History of coronary artery bypass graft (CABG) surgery18.2 (0.1)13.5 (0.3)17.9 (0.24)12.2 (0.13)7.6 (0.1)9.2 (0.12)Metastatic cancer or acute leukemia1 (0.01)0.6 (0.07)1.1 (0.05)0.5 (0.02)0.5 (0.02)1 (0.04)Cancer5.1 (0.03)3.5 (0.15)5.2 (0.1)2.6 (0.05)2.2 (0.05)3.7 (0.07)Diabetes mellitus (DM) or DM complications43.4 (0.1)52.8 (0.43)46.6 (0.29)58.1 (0.21)48.2 (0.21)47.9 (0.21)Protein-calorie malnutrition4.5 (0.06)4.1 (0.21)4 (0.11)3.5 (0.08)3.1 (0.09)2.7 (0.07)Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance32.4 (0.12)32.1 (0.38)29.5 (0.24)36.1 (0.22)30.9 (0.2)30 (0.21)Liver or biliary disease3.4 (0.03)6.4 (0.25)3.9 (0.1)9.3 (0.15)12.1 (0.16)7.4 (0.12)Peptic ulcer, hemorrhage, other specified gastrointestinal disorders3.5 (0.02)3.2 (0.14)3.1 (0.08)2.8 (0.05)2.4 (0.05)2.3 (0.05)Other gastrointestinal disorders27.7 (0.14)25.1 (0.37)23.9 (0.29)26.2 (0.24)21.2 (0.23)20.4 (0.21)Severe hematological disorders1.3 (0.02)0.8 (0.07)1.1 (0.05)0.9 (0.03)0.6 (0.03)0.7 (0.03)Iron deficiency or other/unspecified anemias and blood disease35.2 (0.14)38.4 (0.41)31.1 (0.28)34.7 (0.23)29.7 (0.2)26.5 (0.21)Dementia or other specified brain disorders13 (0.06)10.4 (0.26)8 (0.14)1.4 (0.03)0.9 (0.03)0.5 (0.02)Drug/alcohol abuse/dependence/psychosis6.8 (0.05)9.6 (0.31)8.8 (0.15)24.7 (0.21)37 (0.3)20.6 (0.19)Major psychiatric disorders2.2 (0.03)3.4 (0.16)1.8 (0.08)6.8 (0.08)6.1 (0.11)2.4 (0.06)Depression9.6 (0.07)6.4 (0.21)7.9 (0.15)12.8 (0.13)9.7 (0.12)9 (0.13)Other psychiatric disorders6.7 (0.05)4.4 (0.15)5.8 (0.12)8.4 (0.1)7.4 (0.1)6.9 (0.12)Hemiplegia, paraplegia, paralysis, functional disability3.2 (0.03)4.8 (0.17)3 (0.08)6.5 (0.09)4.1 (0.07)2.6 (0.05)Cardio-respiratory failure and shock25 (0.17)20 (0.35)23.3 (0.34)24.1 (0.22)18.3 (0.2)19.9 (0.19)Congestive heart failure81.1 (0.18)80.3 (0.42)79.7 (0.33)84 (0.21)85 (0.23)86.2 (0.18)Acute coronary syndrome5.5 (0.06)6 (0.19)5.5 (0.13)4.3 (0.07)4.5 (0.09)4.8 (0.08)Coronary atherosclerosis or angina56.8 (0.15)53.2 (0.46)55.7 (0.32)48.1 (0.23)39.3 (0.22)39.9 (0.22)Valvular and rheumatic heart disease28.6 (0.17)22.8 (0.39)24.5 (0.3)15.4 (0.16)16.6 (0.18)19.5 (0.2)Specified arrhythmias and other heart rhythm disorders57.8 (0.13)45.9 (0.43)53.8 (0.32)34.9 (0.24)30.8 (0.21)38.4 (0.26)Other and unspecified heart disease3.7 (0.05)4.2 (0.17)3.7 (0.09)3.7 (0.08)5 (0.11)5.2 (0.1)Stroke0.4 (0.01)0.4 (0.03)0.4 (0.02)0.3 (0.01)0.4 (0.02)0.4 (0.02)Vascular or circulatory disease23.7 (0.12)18.2 (0.32)22.1 (0.26)22.2 (0.16)16.4 (0.14)17.6 (0.16)Chronic obstructive pulmonary disease (COPD)34 (0.11)28.7 (0.46)31.9 (0.29)35.8 (0.22)31.3 (0.23)20 (0.18)Fibrosis of lung or other chronic lung disorders3.3 (0.03)2.3 (0.11)2.9 (0.08)2.5 (0.06)1.7 (0.04)2.4 (0.06)Asthma2.9 (0.03)4.8 (0.16)3.1 (0.08)5.3 (0.08)7.2 (0.11)6.4 (0.09)Pneumonia15.8 (0.08)14.5 (0.28)13.8 (0.18)11.6 (0.11)10.2 (0.1)10.1 (0.11)Dialysis status2.8 (0.03)5.7 (0.19)2.3 (0.07)12 (0.16)3.9 (0.08)2.6 (0.06)Renal failure52.6 (0.14)51.9 (0.44)50.7 (0.32)57.1 (0.24)44.3 (0.28)41 (0.26)Nephritis2.2 (0.03)3.3 (0.14)2.6 (0.09)5.1 (0.08)4.2 (0.08)4.2 (0.07)Other urinary tract disorders5.8 (0.05)5.1 (0.16)5.5 (0.12)4.3 (0.07)4.4 (0.08)4.7 (0.09)Decubitus ulcer or chronic skin ulcer5.1 (0.04)4 (0.15)4.6 (0.1)5.5 (0.07)4.1 (0.07)3.5 (0.06)Supplementary Table 15:Characteristics of Patients Hospitalized for Pneumonia According to the Primary PayereTable 15:**Patients aged ≥65 yearsPatients aged \<65 yearsPatient Characteristics, N (%)MedicareMedicaidPrivate InsuranceMedicareMedicaidPrivate Insurance**No. of Index Admissions, weighted (SD)3159930 (26032)42646 (829)166229 (3083)541983 (5010)401560 (4333)587665 (5549)Age, mean (SE)79.8 (0.02)76.5 (0.08)75.6 (0.08)53.5 (0.03)47.2 (0.05)49.9 (0.04)Female53.1 (0.07)58.4 (0.48)44.4 (0.3)49.3 (0.16)55 (0.17)52.1 (0.14)History of coronary artery bypass graft (CABG) surgery8.3 (0.06)4.4 (0.16)7.6 (0.14)3.4 (0.05)1.8 (0.04)1.9 (0.04)Severe infection; other infectious diseases11.4 (0.05)12.2 (0.27)10.2 (0.15)12.9 (0.11)13.2 (0.14)9.7 (0.09)Septicemia, sepsis, systemic inflammatory response syndrome/shock2.4 (0.03)3.3 (0.15)2.4 (0.08)3.2 (0.06)3.3 (0.07)2.6 (0.05)Metastatic cancer or acute leukemia2.8 (0.03)2.5 (0.14)4 (0.11)2.5 (0.06)3.9 (0.09)5 (0.11)Lung and other severe cancers4.5 (0.03)3.9 (0.18)6.1 (0.13)3.3 (0.06)4.4 (0.09)4.9 (0.08)Lymphoma; other cancers5.2 (0.03)4 (0.16)6.2 (0.13)3.4 (0.06)4.4 (0.07)5.7 (0.1)Diabetes mellitus (DM) or DM complications31 (0.08)39.4 (0.43)31.3 (0.24)34.6 (0.16)26.6 (0.15)22.7 (0.11)Protein-calorie malnutrition9.2 (0.09)9.7 (0.29)8 (0.19)7.6 (0.1)7.2 (0.1)4.7 (0.08)Other significant endocrine and metabolic disorders; disorders of fluid/electrolyte/acid-base balance40.2 (0.12)40.5 (0.44)37.8 (0.26)39.1 (0.19)35.8 (0.19)34.4 (0.16)Other gastrointestinal disorders36 (0.14)32.1 (0.46)32.9 (0.29)37.2 (0.19)29.9 (0.19)29.6 (0.16)Severe hematological disorders1.4 (0.02)0.9 (0.07)1.5 (0.07)1.7 (0.04)2 (0.06)1.5 (0.04)Iron deficiency or other/unspecified anemias and blood disease33.2 (0.14)36.1 (0.44)29.5 (0.27)31.6 (0.2)28.8 (0.18)24.9 (0.16)Dementia or other specified brain disorders24 (0.09)21.9 (0.4)14.2 (0.21)4.3 (0.06)2.5 (0.05)0.8 (0.02)Drug/alcohol abuse/dependence/psychosis8.6 (0.06)9.9 (0.31)11.2 (0.17)28.5 (0.21)39.7 (0.25)23.7 (0.16)Major psychiatric disorders4.1 (0.04)7.5 (0.29)2.8 (0.08)13.9 (0.12)11.3 (0.12)3.8 (0.06)Other psychiatric disorders8.5 (0.06)5.6 (0.2)7.4 (0.15)13.6 (0.13)12.3 (0.14)10 (0.1)Hemiplegia, paraplegia, paralysis, functional disability4.9 (0.03)7.6 (0.22)3.7 (0.09)12.3 (0.12)9.1 (0.12)2.9 (0.05)Respirator dependence/tracheostomy status0.9 (0.02)2.3 (0.14)0.9 (0.05)3.1 (0.06)3.6 (0.08)1.2 (0.03)Respiratory arrest; cardio-respiratory failure and shock31.5 (0.19)26.4 (0.43)30.2 (0.43)34.9 (0.25)28.3 (0.22)27.1 (0.2)Congestive heart failure33.9 (0.1)28.9 (0.42)27.8 (0.24)22 (0.14)15.6 (0.13)10.4 (0.09)Acute coronary syndrome2.5 (0.03)2.3 (0.12)2.2 (0.08)1.2 (0.03)0.9 (0.03)0.8 (0.02)Coronary atherosclerosis or angina32.3 (0.12)24.6 (0.4)28.9 (0.25)18 (0.13)11.3 (0.11)9.6 (0.09)Valvular and rheumatic heart disease7.9 (0.06)5.1 (0.18)6 (0.14)3.3 (0.05)2.3 (0.05)2.5 (0.04)Specified arrhythmias and other heart rhythm disorders33.4 (0.1)23.4 (0.39)28.5 (0.28)12.8 (0.11)9.7 (0.1)10.5 (0.09)Stroke0.5 (0.01)0.6 (0.07)0.5 (0.03)0.2 (0.01)0.2 (0.01)0.2 (0.01)Vascular or circulatory disease16.9 (0.08)12.8 (0.3)15.4 (0.2)13.7 (0.11)9.8 (0.1)9 (0.09)Chronic obstructive pulmonary disease (COPD)41.2 (0.12)35.7 (0.49)40.9 (0.29)39.8 (0.23)34 (0.22)21.7 (0.15)Fibrosis of lung or other chronic lung disorders6.1 (0.04)6.4 (0.21)6 (0.11)5.1 (0.07)4.1 (0.06)4.8 (0.07)Asthma3.9 (0.03)6.8 (0.22)5.1 (0.11)8.2 (0.08)13 (0.13)13.2 (0.1)Pneumonia4.3 (0.05)3.6 (0.16)4.2 (0.11)5.4 (0.07)5.2 (0.07)5.3 (0.07)Pleural effusion/pneumothorax7.3 (0.05)6.7 (0.22)7.4 (0.14)5.8 (0.08)6.1 (0.08)7.5 (0.08)Other respiratory disorders14 (0.08)12.9 (0.32)15.1 (0.21)21 (0.15)16.3 (0.14)18.9 (0.13)Dialysis status1.9 (0.02)3.8 (0.16)1.3 (0.05)7 (0.1)1.9 (0.04)1 (0.03)Renal failure30.3 (0.11)28.7 (0.42)26.4 (0.28)25.5 (0.17)14.9 (0.14)12.2 (0.11)Urinary tract infection12.6 (0.05)14.1 (0.31)8.9 (0.15)8 (0.08)7 (0.09)4.2 (0.05)Other urinary tract disorders5 (0.04)4.5 (0.18)4.8 (0.11)3.3 (0.05)2.7 (0.05)3.1 (0.05)Decubitus ulcer or chronic skin ulcer5.9 (0.04)6.5 (0.21)4.2 (0.11)5.3 (0.07)3.8 (0.06)1.5 (0.03)Vertebral fractures without spinal cord injury0.9 (0.01)0.7 (0.06)0.8 (0.05)0.4 (0.02)0.3 (0.01)0.3 (0.01)Other injuries7.6 (0.07)6.6 (0.21)6.9 (0.15)8.2 (0.11)7.2 (0.1)5.8 (0.09)

Overall, the decrease in readmission rates was significantly higher for target conditions than for nontarget conditions (*P* \< .001). A similar pattern of a larger decrease in readmission rates for target vs nontarget conditions was observed across age-insurance groups (*P* \< .05 for all).

Discussion {#sec0010}
==========

From 2010-2015, 30-day all-cause readmission rates for acute myocardial infarction, heart failure, and pneumonia declined across all age-insurance groups. Readmission rates decreased modestly for conditions not targeted by the HRRP in all age-payer groups, with larger declines among Medicare patients aged ≥65 years. These results are consistent with the hypothesis that interventions designed to reduce readmissions due to the HRRP were implemented broadly rather than exclusively applied to older Medicare fee-for-service beneficiaries.

Under the HRRP, hospitals are financially incentivized to lower excess readmissions among fee-for-service Medicare patients aged ≥65 years. Studies have shown that since the announcement of the HRRP, readmission rates in Medicare have improved for patients aged ≥65 years with conditions specifically targeted under the HRRP, exceeding the decrease in readmission rates for conditions that are not included in the program.[@bib0002], [@bib0015] Our study further extends our understanding of the trends of readmission rates across the non-Medicare population, including privately insured patients who also have value-based payment models with a consideration for readmissions.

Our findings may reflect that hospital-wide efforts were implemented to improve quality of care to decrease readmission rates. Some of the structural changes might have been spurred by CMS itself, which has initiated several programs aimed at reducing readmissions. One such program, Hospital Engagement Networks, was established by the CMS Partnership for Patients in 2011 and focuses on patient safety, particularly the prevention of patient harm after discharge.[@bib0016] The program operated through dissemination of information and the development of collaborations between hospitals. Hospital to Home is a nationwide initiative to develop resources for hospitals to improve transitions through discharge and reduce their readmission rates.[@bib0017] The program emphasized early postdischarge ambulatory care follow-up and patient education. Further, new programs are being initiated to address the burden of unplanned readmissions. The Patient Navigator Program of the American College of Cardiology aims to reduce avoidable hospital readmissions for patients discharged with acute myocardial infarction by supporting a culture of patient-centered care during the hospital stay and in the weeks following discharge.[@bib0018] Adoption of these programs may have led to much wider improvements in readmission rates through improved healthcare delivery, patient education, and improved follow-up, which were not limited to the patients covered under the HRRP directly. This information also represents critical feedback to health policy makers, since health policy interventions may have wider implications for patient health and wellness.

The findings of the study should be interpreted in light of certain limitations. First, we used serial cross-sectional data and assessed secular trends. Therefore, the findings cannot be interpreted to represent a direct causal relationship between health policy implementation and changes in readmission outcomes. Second, hospitalizations are included in the NRD at the time of discharge and cannot be tracked across years. To assess 30-day readmission rates, data from December were excluded. However, this exclusion was consistent across study years and has been recommended by the Agency for Healthcare Research and Quality.[@bib0019] Third, we are unable to specifically account for the competing risk of posthospitalization mortality. However, our analysis compares temporal trends in specific insurance groups, and therefore trends may be consistent across study years. Fourth, changing trends may be subject to directional changes in coding practices. However, it is unclear if such coding changes would disproportionately affect certain patient groups. Fifth, insurance categories defined in the study rely on those reported as the primary payer in the NRD. Moreover, individuals reported as covered under Medicare include both fee-for-service and managed care beneficiaries. Therefore, trends may vary if payers are defined differently. Last, the hospitals cannot be tracked across years, precluding an assessment of hospital-specific readmission rates.

Conclusions {#sec0011}
===========

There was a significant decline in readmission rates for the 3 conditions targeted by the HRRP across age and payer groups. Readmission rates also declined modestly for conditions not targeted by the HRRP. These patterns are consistent with the hypothesis that implementation of the HRRP was associated with systematic changes in the care of patients and reduced readmission risk beyond the HRRP\'s target population of fee-for-service Medicare beneficiaries.

SUPPLEMENTARY APPENDIX {#sec0012}
======================

Supplementary Material accompanying this article can be found in the online version at [10.1016/j.amjmed.2018.06.013](https://doi.org/10.1016/j.amjmed.2018.06.013){#interref0002x}
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[^1]: SE = standard error.
